Healthcare

FDA panel votes to authorize Novavax COVID-19 vaccine

By Cassidy Morrison
Published June 7, 2022 7:41pm ET
Add Washington Examiner on Google
FDA panel votes to authorize Novavax COVID-19 vaccine
A vial of the Phase 3 Novavax coronavirus vaccine is seen ready for use in the trial at St. George's University hospital in London Wednesday, Oct. 7, 2020.

The Food and Drug Administration‘s panel of vaccine experts has voted overwhelmingly to authorize Novavax’s two-dose COVID-19 vaccine, paving the way for a new option that officials hope will attract unvaccinated people.

Already a print subscriber? Click here to login/register your account

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.

Tag:

COVID-19 FDA Public Health Vaccines Washington D.C.